Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

This study has been completed.
Eli Lilly and Company
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: November 14, 2005
Last updated: February 19, 2015
Last verified: January 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2007
  Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):